Registered title, quoted from ClinicalTrials.gov
A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor
An open trial on glioma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07243340, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 4
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (4 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Confirmed recurrent malignant high-grade (WHO grade 3-4) glioma who have received standard therapy and no available treatment.
Inclusion criterion 2
Developed ≥Grade 3 irAE during previous immunotherapy
Exclusion criterion 18
Karnofsky Performance Status (KPS) ≥ 60%
Inclusion criterion 6
Other malignant tumor within 5 years.
Exclusion criterion 10
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07243340, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Key Inclusion Criteria:
- Age ≥ 18 years.
- Confirmed recurrent malignant high-grade (WHO grade 3-4) glioma who have received standard therapy and no available treatment.
- Measurable lesions exist in accordance with RANO criteria.
- Sufficient space for ≥1 mL drug infused into tumor cavity post resection.
- Ommaya reservoir has been placed in the operation area, and drug administration conditions are available.
- Karnofsky Performance Status (KPS) ≥ 60%
- Life expectancy > 12 weeks.
- No severe hematological, cardiovascular, liver or kidney diseases.
- If the patient is a sexually active female of childbearing potential or if the patient is a sexually active male whose partner is a female of childbearing potential, the patient must use appropriate contraceptive measures for the duration of the treatment and for 6 months afterwards. Female patients of childbearing potential must have a negative serum pregnancy test within 7 days of before the C5252 infusion.
- Capable of understanding and complying with protocol requirements.
Key Exclusion Criteria:
- Inability to undergo MRI examination for any reason.
- Active hemorrhage observed before enrollment.
- Imaging test: a. lesion located in non-cerebral regions; b. there are other lesions outside target tumor cavity; c. extra-cranial metastasis.
- Tumor lesion locates in ventricular system or there is a clear perforation between the tumor cavity and the ventricle after tumor resection.
- History of encephalitis, multiple sclerosis or other central nervous system infections
- Treated with steroid hormones and/or more than 5 mg dexamethasone per day or other immunosuppressive drugs for systemic treatment within 4 weeks.
- Persistent or active infection, and cannot be controlled by treatment.
- Subjects with bleeding tendency or need to take anticoagulant drugs, antiplatelet drugs or non-steroidal anti-inflammatory drugs (NSAIDs) and are unable to discontinue.
- Uncontrolled disease, including but not limited to symptomatic congestive heart failure, unstable angina pectoris.
- Other malignant tumor within 5 years.
- Patients who require an attenuated or live vaccine within 28 days prior to the first trial drug administration and during the study treatment period.
- In the period of recurrent herpes simplex virus infection, with corresponding clinical manifestations.
- Systemic use (other than topical) of anti-HSV drugs
- Prior treatment with any oncolytic virus, cell therapy or gene therapy.
- Participants have a history of splenectomy, organ transplantation, bone marrow transplantation or stem cell transplantation
- Prior antitumor treatment with intracranial implants, such as Carmustine.
- Previous history of allergic reactions to similar biological components such as HSV-1, IL-12 or anti-PD-1 antibodies, or with known allergic reactions to any component of the C5252 prescription, including glycerol.
- Developed ≥Grade 3 irAE during previous immunotherapy
- History of frequent drug use (including "recreational use") or drug abuse (including alcohol abuse) within one year prior to signing the informed consent form.
- Other situation that PI consider subjects not appropriate to participate in the study.
Quoted from ClinicalTrials.gov, NCT07243340, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07243340, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.